Opinion|Videos|February 10, 2025
Progression on BTK Inhibitors: Treatment Options and Considerations
Panelists comment on the role of combination venetoclax-ibrutinib in this setting and available supporting data.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on the role of combination venetoclax-ibrutinib in this setting and available supporting data (high level).
- What is the potential role for venetoclax in combination with 2nd generation BTKis in this setting? (
Ahn IE, et al. ASH 2024. Abs 1874 ) - Briefly review recent ESMO guideline updates for managing patients with R/R CLL who experience disease progression on a BTKi. (
ESMO CLL Guideline Update 2024 ) - How does your treatment approach differ for patients who progress on first-line BTK inhibitor therapy versus those who are intolerant to it?
- When would you opt for an alternative BTKi vs changing to a venetoclax-based regimen?
Advertisement
Related to this article
Pooled results from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials confirmed the efficacy of pirtobrutinib in treatment-naive CLL.
A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma
2
FDA Grants Priority Review to Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
3
European Commission Approves Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ mTNBC
4
Teclistamab-Based Induction Elicits High MRD Negativity Rates in Transplant-Eligible Newly Diagnosed Myeloma
5